Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR2 Anti-CD38 A2 CAR-T Cells in RRMM
NCT03464916Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of STI-1492 in multiple myeloma (MM), sponsored by Sorrento Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Oct 2018; status: completed.
02
Drugs
STI-1492
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03464916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464916.